Evidence map›Paper›PMID 41873410›Full record

ArticleOpen forum infectious diseases2026

Re-evaluating the Potential Impact of Preexposure Prophylaxis (PrEP) in Achieving HIV Elimination in the United States: Insights From Modeling.

Jason Baron, Tamar Tchelidze, Neil Parkin, Nicole Robinson, Benjamin La Brot, Aniruddha Hazra, Kenneth H Mayer

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jason BaronRoche Diagnostics, Medical and Scientific Affairs, Indianapolis, Indiana, USA.ORCID https://orcid.org/0000-0002-4182-6349
Tamar TchelidzeRoche Diagnostics, Medical and Scientific Affairs, Indianapolis, Indiana, USA.
Neil ParkinRoche Diagnostics, Scientific Communications, Sebastopol, California, USA.
Nicole RobinsonRoche Diagnostics, Medical and Scientific Affairs, Indianapolis, Indiana, USA.
Benjamin La BrotRoche Diagnostics, Medical Affairs, Pleasanton, California, USA.ORCID https://orcid.org/0000-0002-9553-2274
Aniruddha HazraSection of Infectious Diseases and Global Health, Department of Medicine, University of Chicago, Chicago, Illinois, USA.ORCID https://orcid.org/0000-0001-8557-4465
Kenneth H MayerDepartment of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, The Fenway Institute, Fenway Health, Boston, Massachusetts, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Preexposure prophylaxis (PrEP) to prevent HIV-1 acquisition is a critical component of the strategy to achieve epidemic control and elimination goals. Previous studies assessing PrEP needs have not considered people based on individualized, quantitative risk profiles, potentially overlooking opportunities to increase PrEP use among all individuals vulnerable to acquiring HIV. Method: We modeled the risk distribution of sexually acquired HIV infection based on patterns of sexual activity among sexually active adults living in the United States. We estimated the population impact of PrEP use assuming "optimal" (PrEP perfectly distributed to those at highest risk) or "suboptimal" (distributed to only 50% of highest-risk individuals) PrEP distribution. Results: The model predicts that PrEP use by 1 million and 10 million individuals would prevent ∼3400 and 13 600 sexually acquired HIV infections per year, respectively, with optimal distribution, and 2700 and 9100 infections with suboptimal distribution. In addition to men who have sex with men, heterosexual women make up a significant proportion of the optimally targeted population. Conclusions: Our model provides a framework to estimate the potential population impact of PrEP. While results vary depending on assumptions, our findings strongly suggest that increases in PrEP uptake, substantially beyond current targets, may be required to achieve epidemic elimination goals. Our findings can inform updated assessments of PrEP coverage and provider initiatives at the individual level. Assessment of HIV acquisition risk based on individual behavior rather than risk-group membership indicates the imperative for wider PrEP distribution than currently occurs.

Indexed as

HIVHIV population riskmodelingPrEPrisk

Identifiers

PMID41873410
PMCPMC13006136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.